Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Lowers Price Target to $13

Benzinga Newsdesk www.benzinga.com Negative 81.6%

Neg 81.6% Neu 0% Pos 0%

Benchmark analyst Bruce Jackson maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative Buy and lowers the price target from $18 to $13.